The FDA's upcoming vote on seven peptides, including BPC-157 and TB-500, could legitimize a new multibillion-dollar market for wellness injectables. Telehealth companies like Hims & Hers, which previously profited from compounded versions of Ozempic and Wegovy, are poised to capitalize on this emerging sector. If approved for compounding, these peptides could fuel a new wave of telehealth services, though concerns remain about the long-term safety data for combined peptide protocols. AI
IMPACT Could spur a new wave of telehealth services and investment, mirroring the GLP-1 drug market.
RANK_REASON Regulatory body review of compounds that could create a new market. [lever_c_demoted from significant: ic=1 ai=0.4]
- BPC-157
- Dr. Anant Vinjamoori
- Hims & Hers Health
- Jon Keidan
- Michelle Davey
- Ozempic
- Robert F. Kennedy Jr.
- TB-500
- Torch Capital
- United States Food and Drug Administration
- Wegovy
- Wheel
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
